Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial
Summary
On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324.
Description
On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source